<DOC>
	<DOCNO>NCT02058264</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics treatment effect BBI-4000 topically apply subject axillary hyperhidrosis .</brief_summary>
	<brief_title>A Safety , Tolerability Preliminary Efficacy Study BBI-4000 Subjects With Axillary Hyperhidrosis</brief_title>
	<detailed_description>This randomize , vehicle control , double blind study subject axillary hyperhidrosis design assess safety , tolerability effect sweat production topically apply BBI-4000 14 day . Safety assess though vital sign , physical exam , adverse event , local skin reaction laboratory test ( blood chemistry hematology ) . Efficacy assess though gravimetrically measure sweat production Hyperhidrosis Disease Severity Score ( HDSS ) . Pharmacokinetic information also collect .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>Male Female subject 18 45 year age good general health . Primary axillary hyperhidrosis least 6 month duration . Hyperhidrosis Disease Severity Score ( HDSS ) 3 4 baseline . Gravimetric test baseline indicate least 100mg axillary sweat production 5 min period . Use medically appropriate contraceptive method . Prior axillary use botulinum toxin within 2 year study entry . Prior iontophoresis treatment axillary hyperhidrosis within 12 week study entry . Prior surgical procedure hyperhidrosis surgical procedure axillary area reason . Use anticholinergic treatment , betablocker , alphaadrenergic prescription treatment hyperhidrosis . History diabetes mellitus , thyroid disease , malignancy , glaucoma , intestinal obstructive motility disease , obstructive uropathy , myasthenia gravis , prostate hypertrophy , neurological condition cardiac abnormality . Known condition may cause hyperhidrosis . Use investigational drug within 30 day prior entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>